COMPOUNDING CHEMOTHERAPY MARKET ANALYSIS

Compounding Chemotherapy Market, By Drug Type (Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs), By Compounding Setting (Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings), By Route of Administration (Intravenous (IV), Oral, Subcutaneous (SC), Intramuscular (IM), Intrathecal (IT)), By Patient Type (Adult Patients, Pediatric Patients, Geriatric Patients), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma, Other specific cancer types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Compounding Method (Aseptic Compounding, Non-aseptic Compounding), By Packaging Type (Vials, Ampoules, Pre-filled Syringes, Bottles), By Regulatory Compliance (USP Chapter <797> Compliance, FDA Regulations, EMA Regulations), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

New product launches/Approvals

In November 2022, ImmunoGen Inc., a biotechnology company, announced that the US Food and Drug Administration has granted approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
In December 2022, Novartis AG, a pharmaceutical company, announced that the European Commission (EC) had approved Pluvicto, a targeted radioligand therapy. Pluvicto is approved in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition for the treatment of adult patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC).

Acquisition and partnerships

In July 13, 2023, Revelation Pharma, a pharmaceutical company, acquired Eagle Pharmacy, LLC., a compounding pharmacy, and Lee Silsby Pharmacy, a compounding pharmacy that serves healthcare facilities. Eagle Pharmacy, LLC., is an outsourced compounding pharmacy that provides services to patients, prescribers, medical facilities, and over 29 states and territories in the U.S. Revelation will be able to leverage Eagle's capabilities to guarantee medication availability for office use, as well as to diversify and create new growth avenues for the rest of the Revelation platform. Lee Silsby Pharmacy is also a compounding pharmacy that serves patients and prescribers in over 45 U.S. states and territories.
On October 20, 2023, FarmaKeio Custom Compounding, a pharmaceutical company, announced the acquisition of its newest location in Conway. The goal of FarmaKeio Custom Compounding is to promote the healthcare revolution by offering patients and practitioners nationwide individualized compounded pharmaceuticals and exceptional service.

Compounding Chemotherapy Market Report Snapshots